FAQ/Help |
Calendar |
Search |
Today's Posts |
10-19-2016, 09:20 AM | #1 | ||
|
|||
Member
|
Over the past two decades, biotech companies and clinicians have tried to develop a cure for Parkinson's disease based on Glial cell line-Derived Neurotrophic Factor (GDNF), a naturally occurring factor promoting the growth of dopamine neurons. Some clinical results were stunning, with patients experiencing a spectacular improvement in their symptoms and a return to 'normal' life. However, delivery of GDNF has been a major challenge. As it cannot be absorbed orally, a variety of delivery methods have been tested including direct pumping into the brain, intranasal delivery and gene therapy. Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson's patients, a treatment that will bring benefits to a larger population than the current intra-brain delivery of GDNF.
Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics This New Biotech wants to Regrow Neurons to cure Parkinson's Last edited by Tupelo3; 10-19-2016 at 01:01 PM. |
||
Reply With Quote |
10-19-2016, 03:39 PM | #2 | ||
|
|||
Member
|
Tupelo, do you know when phase 2 trials begin and will they conduct any trials in the states. Thanks for posting this. This is encouraging
|
||
Reply With Quote |
10-20-2016, 02:47 AM | #3 | |||
|
||||
Grand Magnate
|
It seems that a Phase II clinical trial is scheduled to start next year Medicxi founds Parkinson’s startup, commits €9M | FierceBiotech.
__________________
Knowledge is power. |
|||
Reply With Quote |
10-20-2016, 09:05 AM | #4 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | Betsy859 (11-04-2016) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
MedGenesis Partners with Pfizer to Develop GDNF Treatment and Delivery System for PD | Parkinson's Disease | |||
New Treatment Approach For Alzheimer's Disease | Parkinson's Disease |